2 results
Approved WMORecruiting
To compare the efficacy of DS-1062a with that of docetaxel, as measured by PFS and OS, for subjects with NSCLC with or without actionable genomic alterations
Approved WMORecruiting
Primary:To assess the efficacy of DS-1062a, as measured by the ORR, as a treatment for subjects with NSCLC with actionable genomic alterations that has progressed on or after 1platinum-containing therapy and 1 platinum-containing therapy and 1 or…